Skip to main content
Premium Trial:

Request an Annual Quote

Psychiatric Genomics Secures $17 Million in Series B Cash

NEW YORK, Nov. 19-Psychiatric Genomics said today that it has raised $17 million in its first round of Series B financing.


The round is led by Catalytix, a Cayman Islands investment fund. Other investors include the Stanley Medical Research Institute, Oxford Bioscience Partners, the Maryland Department of Business and Economic Development, and others.


The company expects to raise additional money in this round, which will remain open until the end of the year.


Psychiatric Genomics is working to discover genomics-based therapeutics for common mental illnesses like bipolar disorder, autism, and depression. It uses microarrays to probe gene expression in postmortem human brain samples, and has a pharmacogenomics program using cultured neuronal cells.


The company is based in Gaithersburg, Md.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.